A low cholesterol risk score can mislead

There is a particular trap in reviewing cholesterol in someone who feels well. A low ten-year cardiovascular risk estimate can make further discussion seem unnecessary. Yet cardiovascular risk reflects years of exposure to plaque-forming lipids. A short-term risk calculation and a lifetime of exposure are asking different questions.

That distinction matters when deciding how early to assess cholesterol and when treatment might become worthwhile.

The PREVENT framework described uses ten-year risk estimates for adults aged 30–79, but the calculation is only a starting point. Family history, ancestry and other clinical conditions can change its interpretation.

Chronic inflammatory disease is a good example. Inflammation accelerates atherosclerosis, meaning standard risk calculations may underestimate cardiovascular risk. Similar caution applies to older calculations in people of South Asian ancestry. An apparently acceptable low-density lipoprotein (LDL) cholesterol result therefore does not necessarily settle the decision.

There are also patients for whom the cholesterol result itself demands attention. An LDL above 4.9 mmol/L is a marker of severe hypercholesterolaemia and warrants treatment. Familial hypercholesterolaemia can produce high cholesterol from childhood, making early recognition and appropriate genetic assessment important.

What should we actually measure?

Routine lipid results provide more information than LDL alone. Non-high-density lipoprotein (non-HDL) cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It captures cholesterol carried by potentially plaque-forming lipoproteins.

The targets depend on risk rather than a single laboratory reference range. In the risk-based approach described, borderline-to-intermediate risk corresponds to LDL below 2.6 mmol/L and non-HDL below 3.4 mmol/L. For high-risk patients, those targets fall to 1.8 and 2.6 mmol/L respectively.

Additional tests answer different questions.

Lipoprotein(a) is largely genetically determined, so a once-in-a-lifetime measurement can reveal inherited risk that routine cholesterol testing may miss.

Apolipoprotein B measures the number of plaque-forming particles. It can be particularly useful when raised triglycerides or diabetes make the routine lipid picture difficult to interpret.

Coronary calcium scoring provides a different perspective by identifying calcium within existing coronary plaque. It may refine decisions in selected borderline- or intermediate-risk patients, but should not become a routine investigation for everyone. Incidental coronary calcium on a chest CT also deserves follow-up.

None of these investigations removes the need to review the patient over time. Risk factors change, treatment changes and a reassuring result today should not automatically end the conversation.

For a relatively young adult with apparently reassuring cholesterol but a concerning family history, the useful decision is whether the wider risk profile justifies further assessment, a different treatment target or earlier intervention.